Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in advanced esophageal carcinoma
NCT06112704Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2024
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, solid tumor, sponsored by Hansoh Pharmaceutical Group. Started Feb 2024; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT06112704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112704.